Brain tumor drug gets PRIME designation

24 July 2017

US cancer-selective gene therapy company Tocagen (Nasdaq: TOCA) has announced that its Toca 511 (vocimagene amiretrorepvec) treatment of patients with high grade glioma (HGG), a type of brain tumor, has received PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA).

Toca 511, an investigational biologic, and an investigational small molecule, Toca FC, are designed to be used together. They are Tocagen’s lead product candidate, a cancer-selective immunotherapy currently under evaluation in an international, randomized Phase II/III clinical trial which is designed to serve as a potential registrational study. The trial involves patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection.

The PRIME designation application included clinical data from a Phase I resection study in patients with recurrent brain cancer and results from various preclinical models.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK